GE Healthcare Ireland Limited recalls GE Healthcare Omnipaque (iohexol) Injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Presence of particulate matter
- Products
-
- GE Healthcare Omnipaque (iohexol) Injection
- Where it was sold
-
U.S. Nationwide.
Nationwide
- Units affected
- 866,570 vials
- About this recall
- GE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1413-63.